PBA
IOVA icon

Paradigm Biocapital Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-907,428
Closed -$15.1M – 25
2022
Q1 		$15.1M Buy
907,428
+63,423
+8% +$981K 4% 9
2021
Q4 		$16.1M Buy
+844,005
New +$18.6M 4.6% 9

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Paradigm Biocapital Advisors's IOVA Position: Q2 2022 in Review

Paradigm Biocapital Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 907,428 shares — an estimated $15.1M sold.

Paradigm Biocapital Advisors first reported a position in IOVA in Q4 2021 and held it in 2 quarters. The position peaked at $16.1M in Q4 2021. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • Paradigm Biocapital Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 907,428 Iovance Biotherapeutics shares in Q2 2022, an estimated $15.1M.
  • Paradigm Biocapital Advisors first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Iovance Biotherapeutics position peaked at $16.1M in Q4 2021.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.